Phathom Pharmaceuticals, Inc. Common Stock (PHAT) is a publicly traded Healthcare sector company. As of May 20, 2026, PHAT trades at $11.51 with a market cap of $908.42M and a P/E ratio of -3.77. PHAT moved +0.35% today. Year to date, PHAT is -27.43%; over the trailing twelve months it is +159.68%. Its 52-week range spans $2.21 to $19.50. Analyst consensus is strong buy with an average price target of $24.25. Rallies surfaces PHAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes PHAT SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $11.51 |
| Market Cap | $908.42M |
| P/E Ratio | -3.77 |
| EPS | $-3.03 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.50 |
| 52-Week Low | $2.21 |
| Volume | 186.89K |
| Avg Volume | 0 |
| Revenue (TTM) | $175.11M |
| Net Income | $-221.25M |
| Gross Margin | 87.09% |
6 analysts cover PHAT: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.25.